News

The Switching boosted PI to Rilpivirine In Combination with Truvada as a Single Tablet Regimen (SPIRIT) trial identified that once-daily single tablet regimen Complera maintains HIV suppression among

Oxacillin for Injection, USP, is a semisynthetic penicillin indicated in the treatment of infections caused by penicillinase producing staphylococci which have demonstrated susceptibility to the drug. The US

Abilify ODT, which utilizes Catalent’s Zydis fast dissolve drug delivery technology, is designed to improve manic symptoms associated with bipolar disorder as well as to treat schizophrenia. Catalent

The collaboration aims at developing new class of ADHD treatments which demonstrate increased efficacy due to higher affinity for the target receptor, in addition to improved safety due

Under the agreement, Suzhou will use anti-inflammatory compounds and the method to develop small molecule compounds to treat allergic rhinitis and atopic dermatitis. Financial terms and molecular targets

Bilastine is an anti-histamine product, designed for the treatment of symptoms of allergic rhinoconjunctivitis and urticaria. Under the agreement, Faes Farma will receive an initial payment of €10m,

The PAREXEL BioPharm Unit provides the defined expertise, global infrastructure, operational excellence and technologies needed to help small biopharmaceutical companies advance their drugs through the development cycle. The

The double-blind, placebo-controlled trial is designed to evaluate the efficacy, safety and tolerability of NKTR-181 in patients with moderate to severe chronic pain from osteoarthritis of the knee.

The rapid fire test, which was conducted at Medicago’s facility in Durham, North Carolina, is the fifth milestone under a technology investment agreement with DARPA to demonstrate the